Opus Genetics
Develops mutation-specific retinal gene therapies alongside partnered and investigational ophthalmology medicines.
$3.81
After-hours close+0.10 (+2.70%)
At close$3.71(−3.64%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.14 | — | — |
| Aug 2026 | −$0.16 | −$0.14 | +10.6% |
| May 2026 | −$0.16 | −$0.19 | −18.8% |
| May 2026 | −$0.16 | −$0.75 | −368.7% |
| Nov 2025 | −$0.14 | −$0.12 | +14.3% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.14 | — | — | $1.8M | — | — |
| Aug 6, 2026 | −$0.16 | −$0.14 | +10.6% | $2.6M | $755.0K | −71.3% |
| May 21, 2026 | −$0.16 | −$0.19 | −18.8% | $3.1M | $3.9M | +22.9% |
| May 12, 2026 | −$0.16 | −$0.75 | −368.7% | $2.9M | $2.2M | −26.3% |
| Nov 12, 2025 | −$0.14 | −$0.12 | +14.3% | $3.1M | $3.1M | +0.2% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 13, 2025 | ||||||
| May 15, 2025 | ||||||
| Mar 31, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 13, 2024 | ||||||
| May 10, 2024 | ||||||
| Mar 9, 2024 | ||||||
| Nov 13, 2023 | ||||||
| Jun 30, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Dec 31, 2022 | ||||||
| Sep 30, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||